CHICAGO — A single infusion of letetresgene autoleucel demonstrated antitumor activity among patients with advanced or metastatic myxoid/round cell liposarcoma, results from a pilot study suggested.
Data from the trial’s primary analysis — presented at ASCO Annual Meeting — showed superior efficacy outcomes among patients who received standard lymphodepletion before treatment with the investigational T-cell receptor (TCR) therapy.
Treatment of myxoid/round cell liposarcoma typically starts with surgical resection followed by adjuvant chemotherapy or radiation.
Many